FDA Webview
X
about-us-banner

FDA Related News

Home / Articles / FDA Related News
latest-news-card-1
Federal Register

Device Consensus Standards Modifications

Federal Register notice: FDA announces a publication containing modifications it is making to the list of standards FDA recognizes for use in premarke...

latest-news-card-1
Federal Register

Invega Not Withdrawn Due to Safety/Efficacy

Federal Register notice: FDA determines that Janssen Pharmaceuticals Invega (paliperidone) extended-release tablet was not withdrawn from sale due to ...

latest-news-card-1
Human Drugs

Janssens TB Drug Converted to Full Approval

FDA converts Janssens Sirturo (bedaquiline) from accelerated to traditional approval following a determination that a confirmatory trial verified clin...

latest-news-card-1
Federal Register

Switching Studies for Interchangeable Biosimilars Guide

Federal Register notice: FDA makes available a draft guidance entitled Considerations in Demonstrating Interchangeability With a Reference Product: Up...

latest-news-card-1
Federal Register

Guide on Adulteration when Inspection Refused

Federal Register notice: FDA makes available a final guidance entitled Circumstances That Constitute Delaying, Denying, Limiting, or Refusing a Drug o...

latest-news-card-1
Federal Register

Guide on Human User Safety in Animal Drugs

Federal Register notice: FDA makes available a final guidance entitled Human User Safety in New and Abbreviated New Animal Drug Applications.

latest-news-card-1
Human Drugs

Workshop on NDA/BLA Meeting Management Practices

FDA announces a 7/22 public workshop on Best Practices for Meeting Management Under PDUFA VII.

latest-news-card-1
Human Drugs

Lillys Files Mounjara NDA for Sleep Apnea

Eli Lilly says it has submitted an NDA for weight loss therapy Mounjaro (tirzepatide) for treating moderate-to-severe obstructive sleep apnea and obes...

latest-news-card-1
Human Drugs

Lexicon Refiles NDA for Sotagliflozin

After receiving a 2019 complete response letter, Lexicon Pharmaceuticals resubmits its NDA for sotagliflozin oral tablets as an adjunct to insulin the...

latest-news-card-1
Biologics

Dj vu: Marks Overrides Reviewers on Duchenne Drug Again

CBER director Peter Marks again overrides his Centers review teams in approving a supplemental BLA that expands the approval and converts to full appr...